Drugs that both activate and block the GIP receptor reduce weight through different brain mechanisms, offering a new direction for targeted obesity treatments. Drugs that target the receptors for the hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) have proven effective in treating obesity and type 2 diabetes. While GLP-1 and GIP receptor agonists … Read more
May 2, 2025 According to the provided text from Fox News, the World Health Organization (WHO) is planning to endorse the use of GLP-1 weight-loss medications for adults as a strategy to combat the global obesity crisis. This support aims to improve access to these drugs, particularly in low- and middle-income countries, where a significant portion of the world’s obese population resides. The … Read more
The company’s health services division Evernorth is unveiling new programs in a reliable growth area: assuaging payer concerns around GLP-1 coverage. Dive Brief: This article focuses on Cigna’s strategies regarding the growing demand for GLP-1 weight loss medications. Cigna’s health services division, Evernorth, is launching two new support programs aimed at assisting patients and easing concerns for payers regarding the high … Read more
Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide, which is traditionally a treatment for type 2 diabetes, was given to participants who had been diagnosed with a life-threatening form of liver disease called metabolic dysfunction associated … Read more
While the use of Glucagon-like peptide-1 (GLP-1) receptor agonists for treating Type 2 diabetes is well established, strong evidence also supports use of these medications for weight loss. Employer-based health insurance coverage for these prescription drugs currently lags behind this evidence: only one fourth of large employers offer coverage of GLP-1s for weight loss to … Read more
Company says that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management Novo NordiskNOVO.B2.62%increase; green up pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a …
On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers manage GLP-1 utilization. Cigna also posted first quarter results well above analyst forecasts.
Although glucagon-like peptide-1 (GLP-1) receptor agonists are primarily intended for managing type 2 diabetes (T2D) and obesity, research continues to uncover additional benefits. The latest exploration suggests that GLP-1 medications may help lower dementia risk.
